Iterion Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Beta Cat Pharmaceuticals, Inc. (to 2024)
0
Ending by 2030
Jul 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 24, 2027The maintenance fee for Lyophilized Formulations of Tegavivint (US 11,793,759) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due Jul 19, 2027The maintenance fee for Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia. (US 9,238,030) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Formulations of tegavivint (US 11,964,054) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,238,030 | Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia. In force · High confidence | In force | High confidence | |
| US 9,725,473 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses In force · From the USPTO record | In force | From the USPTO record | |
| US 9,963,475 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses In force · From the USPTO record | In force | From the USPTO record | |
| US 11,298,346 | Methods for treatment of fibrotic diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 11,571,388 | Lyophilized Formulations of Tegavivint In force · High confidence | In force | High confidence | |
| US 11,602,501 | Lyophilized Formulations of Tegavivint In force · High confidence | In force | High confidence | |
| US 11,793,759 | Lyophilized Formulations of Tegavivint In force · High confidence | In force | High confidence | |
| US 12,208,166 | Lyophilized Formulations of Tegavivint In force · High confidence | In force | High confidence | |
| US 12,246,010 | Formulations of Tegavivint and Related Compounds In force · High confidence | In force | High confidence | |
| US 11,266,637 | Formulations of Tegavivint and Related Compounds In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 no status recorded